

Tuesday 15 April 2008

European Group for Breast Cancer Screening
09:30-17:00

Welcome address

Rutgers, E.J.T. NL

Chair Heywang - Köbrunner, S. DE Introduction

Chair Wilson, R. UK

SESSION ONE: Breast imaging and screening - Technology update

Chair Heywang - Köbrunner, S. DE

Digital mammography - technical update

Speaker van Engen, R. NL

Digital mammography - clinical results

Speaker Skaane, P. NO

Tomosynthesis

Speaker Thibault, F. FR

Other imaging techniques for screening?

Speaker Schreer, I. DE

SESSION TWO: Management of women at increased risk

Chair Untch, M. DE

Assesing risk

Speaker Meijers-Heijboer, H. NL

Management options - surveillance, chemo-prevention or prophylaxis?

Speaker Schmutzler, R. DE

Speaker Heywang - Köbrunner, S. DE

Debate - Europe wide consensus on managing increased risk?

H. Meijers (NL) - R. Schmutzler (DE) - S. Heywang-Kobrunner (DE)

SESSION THREE: Diagnosis and treatment of screen-detected breast cancer

Chair Rosselli del Turco, M
 Chair Schreer, I

New vacuum assisted mammotomy techniques and their role in the management of screen detected borderline lesion

Speaker Steyaert, L. B

Assessing prognosis of screen detected breast cancer and predicting who needs aggressive treatment

Speaker Pinder, S. UK

Oncoplastic considerations for screen detected breast cancer

Speaker Macmillan, D. UK

SESSION FOUR: Discussion topics in breast screening

Chair Heywang - Köbrunner, S. DE
 Chair Wilson, R. UK

Overview of European screening results

Speaker de Wolf, C. CH

Over-treatment - can it be avoided?

Speaker Pontj, A. IT

ESSO workshop *Surgical principles in oncoplastic surgery*
13:00-17:00

SESSION I

Chair Leidenius, M. FI

Evolution and impact of oncoplastic techniques in breast cancer treatment

Speaker Audretsch, W. DE

A new generation of surgeons: the training in oncoplastic surgery

Speaker Rainsbury, R. UK

SESSION II: The skin sparing mastectomies: Questions and Answers

Chair	Cataliotti, L.	IT
Chair	Rutgers, E.J.T.	NL
Panel	Clough, K.	FR
	Veronesi, P.	IT
	Nava, M.	IT

SESSION III: Highlights

Chair	Querci Della Rovere, G.	UK
Chair	Jaskiewicz, J.	PL
The oncoplastic timing in breast cancer conservative treatment		
Speaker	Calabrese, C.	IT
Reconstruction and radiotherapy		
Speaker	Kirova, Y.	FR
Is microsurgery an oncoplastic tool?		
Speaker	Blondeel, P.	B
Lipofilling in breast reconstruction		
Speaker	Rigotti, G.	IT

ESTRO workshop *Recent advanced in breast cancer radiotherapy*
09:00-17:00

SESSION I – Target volume and OAR definition and delineation

Chair:	Fourquet, A	FR
Setting the scene		
Speaker	Fourquet, A	FR
Breast and primary tumour bed		
Speaker	Boersma, L	NL
Lymph node areas		
Speaker	Kirova, Y	FR
Discussion: Is the time there to set guidelines?		
	Fourquet, A	FR

SESSION II – Fitting radiotherapy in the multimodality environment

Chair:	Budach, W	DE
“Real life examples”		
Speaker	Budach, W	DE
Chemotherapy		
Speaker	Calais, G	FR
Targeted therapy		
Speaker	Westenberg, H	NL
Hormonal treatment		
Speaker	Azria, D	FR
The optimal integration of local and systemic therapy.		
Speaker	Budach, W	DE

SESSION III – Late side effects

Chair:	Yarnold, J	UK
The changing focus from treatment of cancer to prevention of complications		
Speaker	Yarnold, J	UK
Biology		
Speaker	Hall, J	FR
Epidemiology and predictive factors		
Speaker	Overgaard, J	DK
Physical aspects		
Speaker	Hurkmans, C	NL
The search for the optimal compromise		
Speaker	Yarnold, J	UK

SESSION IV – Debates, discussions and case presentations

Chair:	Poortmans, P	NL
Should low-intermediate risk patients after mastectomy be irradiated?		
Yes:	Poortmans, P	NL
No:	Kunkler, I	NL

Is BCT appropriate for BRCA carriers?

Yes:	Fourquet, A	FR
No:	Nestle-Krämling, C	DE

Rare breast cancers: the RCN experience

Speaker	Belkacémi, Y	FR
---------	--------------	----

Discussion on cases submitted by the participants

Budach, W	DE
Fourquet, A	FR
Poortmans, P	NL

Closing remarks

ADVANCING CLINICO GENOMIC TRIALS ON CANCER:
Open grid services for improving medical knowledge discovery
session
12:00-17:00

Welcome

Chair	Tsiknakis, M	GR
-------	--------------	----

What is a Clinico-Genomic Trial and what are its needs?

Speaker	Desmedt, C	BE
---------	------------	----

Current problems in Translational Research in Europe

Speaker	Passiukov, A	BE
---------	--------------	----

The ACGT Vision and technologies

Speaker	Tsiknakis, M	GR
---------	--------------	----

The ACGT architecture: how does it work?

Speaker	Sengstag, T	CH
---------	-------------	----

The ACGT Clinical Trial Management System

Speaker	Graf, N	DE
---------	---------	----

Ethical preconditions and implications of conducting clinico-genomic trials

Speaker	Kollek, R	DE
---------	-----------	----

The ACGT Master Ontology on Cancer: a necessary tool to cover semantics on clinical trials on cancer

Speaker	Brochhausen, M	DE
---------	----------------	----

Nathwani Prize winner 2008

To be announced

Keynote Symposium

10:30 - 12:30

- *Can we walk away from economics?*

Chair:	Piccart, M	BE
Chair:	Winer, E	US

10:30
Effectiveness or cost-effectiveness as the criterion for introducing new therapies for breast cancer?
Keynote lecturer: Tannock, I CA

10:50
The companies view
Speaker: Bizzari, JP US

11:05
Coping with expensive drugs around the world
Speaker: Wilking, N SE

11:20
The society's view
Speaker: Richards, M UK

11:35
The patient's view
Speaker: Knox, S IT

11:50
The doctor's conclusion
Speaker: Winer, E US

12:05
Round table chaired by Winer, E and Piccart, M

Debate

13:00 - 14:00

- *This house believes that "Adjuvantonline!" is standard of care in decision making*

Moderator:	Jackisch, C	DE
Speaker in favour:	Chia, S	CA
Seconder:	Ravdin, P	US
Speaker against:	Di Leo, A	IT
Seconder:	Colleoni, M	IT

Clinical Science Symposia

16:00 - 17:30

- *Towards a rational endocrine therapy treatment*

Expert:	Dowsett, M	UK
Expert:	Lønning, PE	NO

16:00

Biomarkers to guide rational endocrine therapy of breast cancer

Speaker:	Dowsett, M	UK
----------	------------	----

16:20

Endocrine treatment of premenopausal breast cancer patients

Speaker:	Gnant, M	AT
----------	----------	----

16:40

Are there significant differences between third generation aromatase inhibitors?

Speaker:	Lønning, PE	NO
----------	-------------	----

17:00

2 Proffered Paper presentations

- *Breast cancer surgery : Quo Vadis?*

Expert:	Dixon, M	UK
Expert:	Feller, A	DE

16:00

The key role of the surgeon in translational research

Speaker:	Dixon, M	UK
----------	----------	----

16:20

Oncoplastic surgery: extending breast conservation possibilities
Speaker: Clough, K FR

16:40
3 Proffered Paper presentations

- *Pharmacogenetics - the host matters*

Expert: Flockhart, D US
Expert: Danesi, R IT

16:00
Germline SNP analysis as a biomarker for the prediction response to therapy in breast cancer
Speaker: Kristensen, VN NO

16:20
Epigenetics and breast cancer - prediction of drug activity
Speaker: Danesi, R IT

16:40
Pharmacogenomics in the endocrine treatment of breast cancer
Speaker: Flockhart, D US

17:00
2 Proffered Paper presentations

Europa Donna Session

17:45 - 18:45

- *Europa Donna "wrap-up" session*

Chair: Zernik, N FR

17:45
Summary from "Towards a rational endocrine therapy treatment"
Speaker Lønning, P.E NO

17:55
Questions and answers

18:05

Summary from Breast cancer surgery - Quo Vadis?

Speaker A.M. Feller DE

18:15

Questions and answers

18:25

Summary from "Pharmacogenetics - the host matters"

Speaker Flockhart, D US

18:35

Questions and answers

Thursday 17 April 2008

Challenge the expert with difficult clinical cases

08:00 - 08:45

- *Early disease*

Moderator:	Smith, I	UK
Expert:	Dixon, M	UK
Expert:	Fourquet, A	FR
Expert:	Kaufmann, M	DE
Expert:	Piccart, M	DE
Expert:	Goldhirsch, A	IT
Expert:	Davidson, NE	US
Expert:	Norton, L	US
Expert:	Hayes, DF	US
Expert:	Jonat, W	DE
Expert:	Rozman, S	SI

Teaching Lectures

08:00 - 08:45

- *Optimal Her2 testing*

Chair:	tba	
Speaker:	Viale, G	IT

- *State of the art adjuvant therapy*

Chair:	tba	
Speaker:	Gianni, L	IT

- *Mammographic screening in Europe - where are we?*

Chair:	tba	
--------	-----	--

Speaker: Den Heeten, A NL

- *Diagnosis and management of in-situ diseases*

Chair: tba
 Speaker: Cataliotti, L IT
 Speaker: Eusebi, V IT

- *How to overcome the hurdles of running a clinical trial*

Chair: tba
 Speaker: von Minckwitz, G DE

Europa Donna Teaching Lecture

08:00 - 08:45

- *Young women and fertility in breast cancer*

Chair: Bonifacino, A IT
 Speaker: Loibl, S DE

Keynote Symposium

09:00 - 10:30

- *New tools for developing smarter drugs*

Chair: Børresen-Dale, AL NO
 Chair: Petersen, O.W DK

09:00

Identification of biomarkers of therapy response using functional genetic approaches

Keynote lecturer: Bernards, R NL

09:30

Gene expression profiling

Speaker: Sotiriou, C BE

09:50

Targeted imaging

Speaker: Schwaiger, M DE

10:10

Targeting stem cells or the stroma?

Speaker: Polyak, K US

Keynote Symposium**11:00 - 12:30**

- *Tailoring local regional therapy*

Chair: Bartelink, H NL
Chair: Jakesz, M AT

11:00
Arrays - are they helpful?
Speaker: Nuyten, D NL

11:20
New imaging techniques for tailoring therapy
Speaker: Kuhl, C DE

11:40
Tailoring radiotherapy
Speaker: Azria, D FR

12:00
The impact of the sentinel node
Speaker: Kissin, M UK

12:20
Question and answers

Debate**13:00 - 14:00**

- *This house believes that every node positive patient should have local regional radiotherapy*

Moderator: Jassem, J PL
Speaker in favour: Whelan, T CA
Seconder: Pierce, L US
Speaker against: Kunkler, I UK
Seconder: C.J.H. van de Velde NL

Europa Donna Teaching Lecture**13:00 - 14:00**

- *Understanding the biology of medical treatment*

Chair:	Borisch , B	CH
Speaker:	Norton, L	US

Clinical Science Symposia

16:00 - 17:30

- *Controversies in the use of neoadjuvant therapy*

Expert:	Bonnefoi, H	FR
Expert:	Untch, M	DE

16:00

Pathological assessment after neoadjuvant therapy: not an easy task

Speaker:	Salomon, A	FR
----------	------------	----

16:20

Surgery and sentinel node assessment after neoadjuvant therapy

Speaker:	Kühn, T	DE
----------	---------	----

16:40

The NCI consensus - report and conclusion

Speaker:	Gralow, J	US
----------	-----------	----

17:00

2 Proffered Paper presentations

- *Progression of the management of early metastatic breast cancer*

Expert:	Coleman, R.E.	UK
Expert:	Rutgers, E	NL

16:00

Recent developments in management of metastatic bone disease

Speaker:	Coleman, R.E.	UK
----------	---------------	----

16:20

The emerging role of surgery
 Speaker: Rutgers, E

NL

16:40

Brain metastases

Speaker: Boogerd, W

NL tbc

17:00

2 Proffered Paper presentations

- *Lifestyle and survival after treatment for breast cancer*

Expert: Goodwin, P.J. CA

Expert: Murphy-Whyte, C IE

16:00

What breast cancer survivors want to know about lifestyle after breast cancer

Speaker: Murphy-Whyte, C IE

16:20

Stress, distress and support groups - are they important?

Speaker: Kissane, D US

16:40

Lifestyle interventions in breast cancer - what do we know and what do we need to know?

Speaker: Goodwin, P.J. CA

17:00

2 Proffered Paper presentations

Friday 18 April 2008

Challenge the expert with difficult clinical cases

08:00 - 08:45

- *Locally advanced disease*

Moderator:	Possinger, K	DE
Expert:	Winer, E	US
Expert:	Bartelink, H.	NL
Expert:	Jassem, J.	PL
Expert:	Castiglione, M	CH
Expert:	Mauriac, L.	FR
Expert:	Hudis, C	US
Expert:	Untch, M	DE
Expert:	von Minckwitz, G	DE
Expert:	Kyriakides, S	CY

Teaching Lectures

08:00 - 08:45

- *Her2 positive breast cancer from optimal diagnosis to optimal treatment*

Chair:	tba	
Speaker:	Cameron, D	UK

- *Update of antiangiogenic therapy*

Chair:	tba	
Speaker:	Burstein, H	US

- *Long term risk and benefits of radiotherapy: lessons from the overview*

Chair:	tba	
Speaker:	Darby, S	UK

- *Do we really need new sophisticated diagnostic tests?*

Chair:	tba	
Speaker:	Van de Vijver, M	NL

Europa Donna Teaching Lecture

08:00 - 08:45

- *Biology not chronology driven treatment*

Chair: Verschuur-van der Voort, E NL
 Speaker: Aapro, M CH

Keynote Symposium

09:00 - 10:30

- *Challenges in breast cancer molecular targeting*

Chair: Hayes, D.F. US
 Chair: Bonnefoi, H FR

09:00

The future of molecular targeting for individualised treatment

Keynote lecturer: Mills, G.B. UK

09:30

Targeting ER and signalling pathway

Speaker: Johnston, S.R.D. UK

09:50

Targeting HER family

Speaker: Baselga, J ES

10:10

DNA repair

Speaker: Ashworth, A UK

Keynote Symposium

11:00 - 12:30

- *Late breaking news – latest research papers and overviews*

Chair: Norton, L US
 Rutgers, E NL

Debate

13:00 - 14:00

- *This house believes that in the presence of targeted therapy, the type of chemotherapy does not matter in endocrine responsive disease*

Moderator:	Davidson, N.E.	US
Speaker in favour:	Hudis, C	US
Seconder:	Cufer, T	SL
Speaker against:	Rodenhuis, S	NL
Seconder:	Möbus, V	DE

Clinical Science Symposia

16:00 - 17:30

- *Triple negative breast cancer, one or several diseases?*

Expert:	Di Leo, A	IT
Expert:	Tutt, A	UK

16:00

Designing clinical trials for triple negative breast cancer: evidence and issues

Speaker:	Di Leo, A	IT
----------	-----------	----

16:20

The molecular pathology of Estrogen receptors, Progesterones, HER2 negative breast cancers - finding novel biomarkers

Speaker:	Reis-Filho, J	UK
----------	---------------	----

16:40

How should we best target the biology of of Estrogen receptors, Progesterones, HER2 negative breast cancer?

Speaker:	Tutt, A	UK
----------	---------	----

17:00

2 Proffered Paper presentations

- *Delivering optimal breast cancer care in all circumstances*

Expert: Costa, A IT
Expert: Maistruk, G UA

16:00

Organisation of breast units

Speaker: Costa, A IT

16:20

The Breast Health Global Initiative: a catalyst for cancer control in limited resource countries

Speaker: Anderson, B US

16:40

Breast cancer in emerging countries: the case of South Africa

Speaker: Apffelstaedt, J SA

17:00

2 Proffered Paper presentations

- *Progression in the biology of metastatic breast cancer*

Expert: Hayes, D.F. US
Expert: Pantel, K DE

16:00

Bone marrow micrometastasis

Speaker: Klaus Pantel, Germany

16:20

Circulating tumour cells

Speaker: D.F. Hayes, US

16:40

Expression profiles predicting metastatic relapse at different sites

Speaker: L. J. van 't Veer, The Netherlands

17:00

2 Proffered Paper presentations

IBUS special workshop

13:00 – 17:00

- *Breast Ultrasound - Update*

Chair Munding, A. DE
Chair Wilson, R. UK

13:00

Welcome address

Speaker Munding, A. DE

13:10

New frontiers in breast ultrasound technology

Speaker Weismann, C. AT

13:40

Adapted ultrasound BI-RADS criteria to improve lesion characterization

Speaker Madjar, H. DE

14:10

Role of ultrasound in the German Mammography Screening Programme

Speaker Heindel, W. DE

14:30

New developments of interventional techniques of the breast

Speaker Wilson, R. UK

Live demonstration

US examination and minimal invasive punctures including vacuum assisted biopsies

Speaker Madjar, H. DE

Speaker Weismann, C. AT

15:30

Technique and value of intraoperative axillary and breast ultrasound

Speaker Durante, E. IT

16:00

New insights in multimodality imaging in DCIS

Speaker Munding, A. DE

16:20

MRI of the breast - where so we stand?

Speaker Kuhl, C. DE

16:40

Discussion and closing remarks

Speaker Wilson, R. UK

SenoNetwork meeting

14:00 – 16:00

Chair: Bernier, J CH
Co-Chair: Rosselli del Turco IT

The pathology report: what do we really need to know?
Speaker Wells, C.A. UK

The tumour board: how to prepare it properly
Speaker Awada, A B

The breast unit database: mission impossible?
Speaker Ponti, A IT

Faculty and Invited speakers

A. Awada (B); J. Bernier (CH); A. Ponti (IT); M. Rosselli del Turco (IT);
C.A. Wells (UK)

TRANSBIG workshop
17:45 – 18:45

Part 1 - restricted to the EBCC audience

- *Patient-Physician-Researcher-Nurse: a key partnership on the road to a cure for cancer?*

Co-Chairs: L. Van 't Veer and Martine Piccart

1. The multidisciplinary approach to translational research: what are the challenges, where are the rewards? - F Cardoso
2. The pathologist: the strongest link - G. Viale
3. How the surgeon brings science into practice - E. Rutgers
4. Clinical trial nursing – a separate discipline? – Y. Wengström
5. For the patient, with the patient - S. Kyriakides

TRANSBIG German workshop
19:00 – 20:30

Part 2 - open to the public

- *Our research – your future cure? Ask the experts!*

Chair: M. Untch

Panel: M. Untch - N. Harbeck - U. Kettritz - D. Schmitt - G. Kemper -

R. Haidinger

19:00

Introduction of panel and session – M. Untch

19:05

How tumor biology guides our therapy decisions” -N. Harbeck

19:20

Mammography screening in Germany: what have we learned from our European neighbours?” – U. Kettritz

19:35

Follow up after breast cancer: what have we learned from patients?”
D.Schmitt

19:50

Questions and Answers

Saturday 19 April 2008

Patient Management Workshop

08:30 - 10:30

- *Early disease*

Coordinator: Fourquet, A FR

A team from Institut Curie in Paris will present two clinical cases and discuss the management options

Patient Management Workshop

09:30 - 10:30

- *Locally advanced disease*

Coordinator: Bergh, J SE

A team from Karolinska Institute in Stockholm will present two clinical cases and discuss the management options

Metastatic Breast Cancer session

Introduction

Chairs: Cardoso, F (BE) and Winer, E (US)

- Can metastatic breast cancer be cured?
(point-counterpoint discussion)

Speaker for: Wood, B (US)

Speaker against: Colleoni, M (IT)

Discussion with panel and audience

- Management of CNS metastases: a new era for a growing problem

General issues & Systemic therapy

Speaker Winer, E (US)

Local therapy

Speaker Devriendt, D (B)

Discussion with panel and audience

- Treating metastatic breast cancer: Is more always better?
(point-counterpoint discussion)

Speaker Albain, K (US) tbc
(for combination)

Speaker Cardoso, F (BE)
(for sequential use)

Discussion with panel and audience

PANEL:

Speakers: Cardoso, F; Winer, E; Colleoni, M; Devriendt, D; Albain, K;

German Breast Group: Thomssen, C

ESO-EBCC MBC Task Force: Cardoso, F; Winer, E; E.Senkus-Konefka;
O.Pagani; A. Wardley; A.Costa; L.Fallowfield; M.Namer; S. Rodenhuis;
S.Kyriakides; T. Cufer

Berlin Statement

11:00 - 13:00

- *How can Europe afford to treat breast cancer?*

To be announced